Investment Rating - The report maintains a "Buy" rating for WuXi AppTec (2268 HK) with a target price of HKD 91.00, indicating a potential upside of 55.9% from the current price of HKD 58.35 [1][2][3]. Core Insights - The report highlights the sustained high activity in the global CXO sector, which is expected to benefit WuXi AppTec as industry demand improves. The company is projected to see over 20% growth in total orders from 2025 to 2027, with a significant increase in late-stage/commercial orders [2][6]. - The revenue and adjusted net profit forecasts for 2025-2027 have been slightly reduced by 1-3%, with expected revenues of RMB 58.79 billion, RMB 82.78 billion, and RMB 111.14 billion respectively, reflecting a strong CAGR of 38% to 46% driven by growth in comprehensive CMC orders [6][10]. - The report emphasizes WuXi AppTec's leading position in the high-growth XDC CRDMO sector, making it a top pick in the CXO industry due to its attractive investment value [6][10]. Financial Summary - Revenue projections for WuXi AppTec are as follows: RMB 5,879 million for 2025, RMB 8,278 million for 2026, and RMB 11,114 million for 2027, with corresponding adjusted net profits of RMB 1,600 million, RMB 2,454 million, and RMB 3,416 million [5][18]. - The gross profit margin is expected to remain stable at 35.1% for 2025, increasing to 39.1% by 2027, indicating improved profitability [5][20]. - The company's market capitalization is approximately HKD 73.4 billion, with an average daily trading volume of 8.31 million shares [5][6].

Core Viewpoint - WuXi AppTec (02268) has seen a significant stock price increase, with a rise of over 8% during trading, currently up 6.6% at HKD 62.2, with a trading volume of HKD 253 million. The company has issued a positive earnings forecast for 2025, leading to a slight adjustment in revenue and adjusted net profit predictions for 2025-2027 by 1-3% [1] Group 1: Financial Forecasts - The adjusted revenue forecasts for 2025-2027 are set at RMB 5.88 billion, 8.28 billion, and 11.11 billion respectively, while the adjusted net profit forecasts are RMB 1.60 billion, 2.45 billion, and 3.42 billion, corresponding to a compound annual growth rate (CAGR) of 38% and 46% for the respective years [1] - The strong growth is primarily attributed to the rapid increase in comprehensive CMC orders, particularly from late-stage clinical and commercialization phase contributions [1] Group 2: Market Trends - In the first two months of 2026, there were 25 financing events in the global XDC sector, a significant increase from 18 events in the same period of 2025 [1] - The number of BD transactions for XDC candidate drugs has remained stable, with a substantial increase in total upfront payments [1] - Since the beginning of 2024, there has been a gradual increase in the number of financing events, BD transactions, and total upfront payments in the XDC field, indicating sustained market activity [1] Group 3: Industry Position - The ongoing activity in financing and BD transactions is expected to further enhance downstream demand in the XDC CRDMO industry [1] - WuXi AppTec, as a leading company with strong technical capabilities and integrated delivery capabilities, is well-positioned to benefit from this important trend and expand its market share [1]